中国药房2017，Vol.28Issue(11)：1456-1459,4.DOI:10.6039/j.issn.1001-0408.2017.11.05
文拉法辛与艾司西酞普兰治疗抑郁症的循证药物经济学评价
Evidence-based Pharmacoecomic Evaluation of Venlafaxine and Escitalopram in the Treatment of Depres-sive Disorder
摘要
Abstract
OBJECTIVE:To systematically evaluate the pharnacoeconomic effect of venlafaxine and escitalopram in the treat-ment of depressive disorders. METHODS:Using"venlafaxine""escitalopram""depression""depressive episode""antidepressant"as key words,retrieved from CNKI,VIP and Wanfang database during base creation date to Dec. 2015,related literatures about venlafaxine and escitalopram in the treatment of depressive disorders were selected. The cure rate of two therapy plans for depres-sive disorders and HAMD score were analyzed statistically by cost-effectiveness analysis of pharnacoeconomics. RESULTS:There was no statistical significance in cure rate and HAMD score between 2 groups(P>0.05),so minimum-cost analysis was adopted. The costs of venlafaxine and escitalopram in the treatment of depressive disorders were 772.03 yuan and 935.77 yuan. CONCLU-SIONS:Therapeutic efficacy of venlafaxine is similar to that of escitalopram in the treatment of depressive disorders,but the for-mer scheme is more economical.关键词
文拉法辛/艾司西酞普兰/抑郁症/最小成本分析/循证药物经济学评价Key words
Venlafaxine/Escitalopram/Depressive disorder/Cost-minimization analysis/Evidence-based pharnacoeconomic evaluation分类
医药卫生引用本文复制引用
杜彪,杜扬,谢星星,范小冬,张春燕,孔文强..文拉法辛与艾司西酞普兰治疗抑郁症的循证药物经济学评价[J].中国药房,2017,28(11):1456-1459,4.基金项目
重庆市科技计划项目(cstc2015shmszx120073) （cstc2015shmszx120073）
重庆市万州区科技计划项目(201403055) （201403055）
